Discoveries to Change Lives.
The worrying and increasing development of bacterial
resistance has led to the search of alternative substances
to antibiotics. One of them is the application of phage-encoded
lytic proteins, known as enzybiotics, on which our company is focused.
Telum Therapeutics SL is a global drug discovery biotechnology
company specializing in the use of Engineered Phage Lytic
Proteins as new antimicrobial products.
Numerous studies place the bacteriophages and, specially, their lytic enzymes, as one of the most promising alternatives to the traditional
antibiotics. For this reason, Telum Therapeutics is creating a broad bacteria and phage collection from anthropogenic and cave explorations to obtain new bacteriophages and lytic enzymes with potential antibacterial therapeutic purposes.
Telum’s mission in the field of antibiotic drug development is to give hope to patients suffering with drug resistant infections by developing new antimicrobial agents.
Advanced Phage Enzybiotics from exploration platform
Advance Phage Enzybiotics from
Bacteria & Lytic/Lysogenic bacteriophage isolation
Bacteriophage genome sequencing and lytic enzyme identification
Phage lytic protein modules
Protein engineering using machine learning
EPLE screening under Relevant conditions
EPLE secondary modifications
Telum Therapeutics Development Pipeline
Within our pipeline we have specific programs to treat serious multidrug-resistant Gram-negative infections caused by Enterobacteriaceae, Acinetobacter baumannii and Pseudomonas aeruginosa
Abbreviations: EPLE: Engineered Phage Lytic Enzyme; GN, Gram negative bacteria; GP, Gram positive bacteria; ESKAPE, Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp